文献速递妇科

子宫内膜癌患者是否应常规使用他汀?澳大利亚记录链接研究

Is there sufficient evidence to recommend women diagnosed with endometrial cancer take a statin: Results from an Australian record-linkage study.
PubMed 文献 · Gynecol Oncol · 2021-04-10

该研究基于澳大利亚癌症数据库16,501例子宫癌患者,链接处方与死亡数据库分析他汀使用与生存关系。诊断后使用他汀与子宫内膜癌特异性死亡率降低相关(时变模型HR=0.92,95%CI 0.82-1.03),但仅见于1型癌、亲水性他汀及诊断后新使用者(HR=0.75,95%CI 0.59-0.95)。作者认为推荐所有患者使用他汀为时过早,但足以支持开展随机试验。

要点

  • 诊断前他汀使用与子宫内膜癌生存无关联。
  • 诊断后他汀使用与1型癌及新使用者特异性死亡率降低相关。
  • 存在反向因果可能,尚不足以推荐所有患者常规使用他汀。

核心结论

  • 诊断后使用他汀的子宫内膜癌患者可能生存更好,但无法完全排除偏倚,尤其反向因果。
  • 目前推荐所有子宫内膜癌患者使用他汀为时过早,但证据足以支持开展随机试验。

研究设计与样本

  • 基于澳大利亚癌症数据库的回顾性记录链接研究,纳入2003年7月至2013年12月(新南威尔士州至2012年)诊断的子宫癌患者共16,501例。
  • 链接国家处方数据库与国家死亡索引获取他汀使用与生存结局,随访至2015年12月。
  • 采用Cox比例风险回归估计风险比(HR)及95%置信区间(CI)。

主要发现

  • 在15,703例子宫内膜癌患者中,诊断前他汀使用与生存无关联。
  • 诊断后他汀使用与子宫内膜癌特异性死亡率降低相关(时变模型HR=0.92,95%CI 0.82-1.03)。
  • 该关联仅见于1型癌(HR=0.87,95%CI 0.76-1.00)、亲水性他汀(HR=0.84,95%CI 0.68-1.03)及诊断后新使用他汀者(HR=0.75,95%CI 0.59-0.95)。
  • 随他汀处方数量增加呈现弱剂量反应关系。
  • 采用逆概率治疗加权(IPTW)的敏感性分析结果相似。

临床怎么用

  • 目前不应常规推荐所有子宫内膜癌患者使用他汀以改善生存。
  • 对于1型癌或诊断后新启用他汀的患者,可与患者讨论潜在获益与不确定性。
  • 临床决策需考虑反向因果等偏倚,等待随机试验证据。

局限性

  • 观察性设计无法完全排除偏倚,尤其反向因果(疾病状态可能影响他汀使用)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A recent paper suggested all women with endometrial cancer should take statins but it is unclear whether there is sufficient evidence to justify this recommendation. METHODS: We identified all women diagnosed with uterine cancer in Australia between July 2003 and December 2013 (2012 in New South Wales) through the Australian Cancer Database (N = 16,501) and linked these to the national prescription database and National Death Index to identify statin use and survival outcomes to December 2015. We used Cox proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the associations between statin use and survival. RESULTS: Among the 15,703 women with endometrial cancer, pre-diagnosis statin use was not associated with survival. Endometrial cancer-specific mortality was lower among women who used statins after diagnosis (time-varying models: HR = 0.92; 95%CI 0.82-1.03) but the association was only seen among women with type 1 cancers (0.87; 0.76-1.00), for hydrophilic statins (0.84; 0.68-1.03) and for new use of statins after diagnosis (0.75; 0.59-0.95). There was a weak dose-response with increasing number of statin prescriptions. Sensitivity analyses using inverse probability of treatment weights were similar. CONCLUSION: Women with endometrial cancer who take statins after diagnosis may have better survival than those who do not use statins. However, it is impossible to completely rule out bias, particularly reverse causation where disease status may affect statin use. We believe it is too early to recommend all women with endometrial cancer take statins, but there is sufficient evidence to justify a randomized trial.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Feng JL, Dixon-Suen SC, Jordan SJ, et al. Is there sufficient evidence to recommend women diagnosed with endometrial cancer take a statin: Results from an Australian record-linkage study. Gynecol Oncol. 2021. PMID: 33846016. doi:10.1016/j.ygyno.2021.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。